News

Activation Capital Secures $1.5M to Support Life Sciences Commercialization and Business Formation

The latest funding highlights a series of investments into the Virginia Bio+Tech Park, complementing the City of Richmond’s investment into its Innovation District vision.

RICHMOND, Va., – An omnibus spending bill funding the federal government for the fiscal year 2023 and signed by the president includes $1.5M for Activation Capital, an innovation ecosystem development organization. The funding will support the continued growth and acceleration of life sciences commercialization and business formation in Central Virginia and including those applicable to the emerging advanced pharmaceutical research, development, and manufacturing cluster in the region.

Added to the bill at the request of Virginia Senators Tim Kaine and Mark Warner, the funds will support Activation Capital’s life sciences commercialization, training, and capacity-building efforts.

“This federal funding is a much-needed seed investment into our entrepreneurship growth strategy focused on building a pipeline of entrepreneurs translating high-potential health and life sciences discoveries into high-growth companies,” said Chandra Briggman, President and CEO of Activation Capital, a state-created innovation ecosystem development organization. “Life sciences is a fairly resilient sector – a worthy investment to grow our regional economy, but we need capacity-building support to help actualize its potential. We deeply appreciate Senator Mark Warner and Senator Tim Kaine for their support of our work to strengthen the life sciences ecosystem and the Virginia Bio+Tech Park and create an economic engine for the region.”

“I am proud to support Activation Capital in their mission to build a resilient life sciences research and development workforce in Central Virginia,” said Senator Warner. “This funding, which we secured as part of our bipartisan omnibus spending package, will aid the crucial work of Activation Capital in establishing Central Virginia as a hub for pharmaceutical manufacturing through investment in local entrepreneurship, talent building, and recruitment – spurring economic growth in Petersburg and throughout the region.”

“Central Virginia is already a critical hub for innovative science. Further investment in advanced manufacturing will not only boost our competitiveness and independence from overseas technologies, but also create opportunities for economic growth. I’m glad Activation Capital is receiving these resources from the government funding bill to invest in life sciences research, support skills training, and create jobs by helping startups grow and strengthen the regional economy,” said Senator Kaine.

The 2023 Omnibus spending package to support life sciences commercialization, training, and capacity building follows recent announcements by Activation Capital detailing a transformative $55.9M Build Back Better Regional Challenge award for the region and a $450K GO Virginia Region 4 Grant to design a regional entrepreneurship strategy.

Read more here.

Recent News

04/29/2025

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital construction project in the 95-year-old university’s history — a new biological sciences building. The planned five-story, 162,586 square-foot building will be located on ODU‘s campus in Norfolk, near the university’s Oceanography and Mills Godwin Life Sciences buildings. ODU spokesperson Jonah Ross Grinkewitz said the

04/29/2025

Compremium AG Appoints Dr. Kolaleh Eskandanian to Lead New Division of Pediatrics and Special Populations

Dr. Eskandanian, a global leader in pediatric innovation, joins Compremium from Children’s National Hospital in Washington, D.C., where she most recently served as Vice President and Chief Innovation Officer, Executive Director of the Sheikh Zayed Institute for Pediatric Surgical Innovation, and founding executive of Innovation Ventures. Her appointment marks a strategic milestone in Compremium’s expansion

04/24/2025

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum. Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the